M&A Deal Summary |
|
---|---|
Date | 2021-10-22 |
Target | Lemonaid Health |
Sector | Healthcare Services |
Buyer(s) | 23andMe |
Deal Type | Add-on Acquisition |
Deal Value | 400M USD |
Advisor(s) | Fenwick & West Nelson Hardiman (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2006 |
Sector | Life Science |
Revenue | 272M USD (2022) |
23andMe is a consumer genetics and research company that helps people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple Food and Drug Administration authorizations for genetic health risk reports. 23andMe has created the world’s largest crowdsourced platform for genetic research, with 80% of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. 23andMe was founded in 2006 and is based in South San Francisco, California.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Healthcare Services) | 1 of 1 |
Type (Add-on Acquisition) | 1 of 1 |
State (California) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2021) | 1 of 1 |
Size (of disclosed) | 1 of 1 |